Viewing StudyNCT03526861



Ignite Creation Date: 2024-05-06 @ 11:27 AM
Last Modification Date: 2024-10-26 @ 12:45 PM
Study NCT ID: NCT03526861
Status: COMPLETED
Last Update Posted: 2023-05-06
First Post: 2018-05-04

Brief Title: Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 ECZema TRAlokinumab Trial no 6
Sponsor:
Organization: LEO Pharma

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 301
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: